TransMedics Group (NASDAQ:TMDX) Research Coverage Started at UBS Group

UBS Group initiated coverage on shares of TransMedics Group (NASDAQ:TMDX) in a report issued on Tuesday, MarketBeat reports. The brokerage issued a neutral rating and a $80.00 price target on the stock.

Several other research firms have also recently weighed in on TMDX. Wall Street Zen cut TransMedics Group from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. TD Cowen reissued a “buy” rating and set a $120.00 target price on shares of TransMedics Group in a research note on Wednesday, July 1st. Piper Sandler restated an “overweight” rating on shares of TransMedics Group in a report on Wednesday, July 22nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of TransMedics Group in a research note on Tuesday, June 9th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $124.00 price target on shares of TransMedics Group in a research note on Tuesday, June 30th. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $129.55.

TransMedics Group Stock Performance

Shares of TransMedics Group stock opened at $76.13 on Tuesday. The company has a market capitalization of $2.63 billion, a PE ratio of 17.30 and a beta of 1.89. TransMedics Group has a 12 month low of $60.10 and a 12 month high of $156.00. The company has a current ratio of 6.74, a quick ratio of 6.19 and a debt-to-equity ratio of 1.70. The stock’s fifty day simple moving average is $72.40 and its 200 day simple moving average is $100.99.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The business had revenue of $173.93 million for the quarter, compared to the consensus estimate of $174.44 million. During the same quarter in the prior year, the firm posted $0.70 earnings per share. The business’s revenue was up 21.2% on a year-over-year basis. On average, research analysts predict that TransMedics Group will post 1.88 EPS for the current year.

Insider Activity at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the sale, the director directly owned 16,642 shares in the company, valued at $1,249,148.52. The trade was a 36.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Harvest Fund Management Co. Ltd acquired a new stake in TransMedics Group in the 3rd quarter valued at approximately $29,000. North Star Investment Management Corp. acquired a new position in TransMedics Group during the 1st quarter worth approximately $30,000. Ascentis Independent Advisors acquired a new position in TransMedics Group during the 1st quarter worth approximately $30,000. Allworth Financial LP grew its stake in shares of TransMedics Group by 74.3% during the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after acquiring an additional 113 shares in the last quarter. Finally, Parallel Advisors LLC grew its stake in shares of TransMedics Group by 42.1% during the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after acquiring an additional 83 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.